Sight Sciences, Inc. SGHT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Sight Sciences, Inc. reported revenue across 2 business segments; the largest, Surgical Glaucoma, was $75.7M, 97.9% of the filed sum (-0.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Surgical Glaucoma$75.7M97.9%-0.2% yoy
- Dry Eye$1.64M2.1%-58.7% yoy
Members sum to the consolidated $77.4M for this period.
- Surgical Glaucoma$18.3M93.1%+7.2% yoy
- Dry Eye$1.35M6.9%+243.7% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.